Navigation Links
Spitfire Pharma, Inc. will present body weight, liver weight and glucose regulation data on the GLP-1/Glucagon Dual Agonist SP-1373 at the American Diabetes Association's 77th Scientific Sessions
Date:4/11/2017

SOUTH SAN FRANCISCO, Calif., April 11, 2017 /PRNewswire/ -- Spitfire Pharma, Inc., ("Spitfire") is pleased to announce that research concerning their novel dual acting oxyntomodulin-based drug candidate SP-1373, has been selected for presentation at the American Diabetes Association's 77th Scientific Sessions. (Sunday Jun 11, 2017 12:00 PM - 1:00 PM, Poster 322-LB in category 22-A, Obesity-Animal)

"Type 2 diabetes, obesity and non-alcoholic steatohepatitis are major medical problems that are still in need of additional therapeutics. Spitfire Pharma LLC has been interested in harnessing the beneficial effects of the body's natural dual acting hormone oxyntomodulin (GLP-1/glucagon dual receptor agonist). A successful drug of this nature could add to the toolkit of physicians caring for such patients," said Dr. Andrew J. Perlman, Spitfire's Chief Medical Officer.

About Spitfire Pharma, Inc. 
Spitfire Pharma, Inc., is a "virtual" company which was created to hold the ownership of the SP-1373 development program. Spitfire is funded by Velocity Pharmaceutical Holdings, LLC (VPD). The SP-1373 development program is managed under contract by VPD. 

About Velocity Pharmaceutical Development, LLC 
VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net

About Velocity Pharmaceutical Holdings, LLC 
Velocity Pharmaceutical Holdings, LLC, is an entity funded by Presidio Partners that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC. More information is available at www.vpd.net and www.presidiopartners.com

Contact
Leslie Loven
1-415-524-7326
leslie@vpd.net

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spitfire-pharma-inc-will-present-body-weight-liver-weight-and-glucose-regulation-data-on-the-glp-1glucagon-dual-agonist-sp-1373-at-the-american-diabetes-associations-77th-scientific-sessions-300437782.html


'/>"/>
SOURCE Spitfire Pharma, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NovoBioPharma, Partnership of Top Life Science Experts, Launches
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
5. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
6. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of ViroPharma, Inc. - VPHM
8. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
9. Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
10. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
11. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... May 21, 2019 , ... ... to share their stories by entering our 17th Annual Essay Contest . ... have chronic kidney disease, including people on dialysis or have a kidney transplant ...
(Date:5/21/2019)... (PRWEB) , ... May 21, 2019 , ... ... and the leading source of financing and ongoing support for Connecticut’s innovative, growing ... a $1 million investment in Invixium Access, a manufacturer of modern biometric solutions. ...
(Date:5/21/2019)... ... ... Molecular You, a personalized digital health company, announced today that it has ... The report, including 5 Healthcare AI vendors, was published May 7, 2019 by Gartner ... . , The Gartner report notes: “AI is a top game-changing technology across ...
Breaking Medicine Technology:
(Date:5/21/2019)... Fla. (PRWEB) , ... May 21, 2019 , ... AltMed Florida has announced ... Longwood, FL (1.5 miles east of Interstate 4 at exit 94) at 10 a.m. Friday, ... to serve the growing communities of Winter Park, Apopka, Sanford and many others along the ...
(Date:5/21/2019)... ... 2019 , ... Just in time for national Better Hearing ... its first children’s story, Everybody Needs a Turn. Written by an ASHA member ... as she deals with feeling left out when her brother gets extra attention ...
(Date:5/21/2019)... ... 2019 , ... Coral Detection Systems recently went to market with the first ... uses advanced AI software and an underwater video camera to analyze, detect, and track ... alert upon any entrance to the water, and more importantly, upon detection of ...
(Date:5/21/2019)... , ... May 21, 2019 , ... Dr. Mauricio Martinez ... of untreated obstructive sleep apnea as well as common symptoms to look out for ... patients who have been diagnosed with sleep apnea and treats the condition with guided ...
(Date:5/21/2019)... ... May 21, 2019 , ... Cieplak Dental Excellence dentist and ... of the ability of orthodontics treatments like Invisalign® to improve the ... patients with crooked teeth interested in straightening them, to receive a personalized consultation ...
Breaking Medicine News(10 mins):